Pulmonary hypertension: Screening and evaluation in scleroderma

Current Opinion in Rheumatology

Volumn 23, Issue 6, 2011, Pages 536-544

  York, Michael ^a   Farber, Harrison W ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pulmonary hypertension; Risk factors; Scleroderma; Screening; Systemic sclerosis; Treatment

Indexed keywords

BIOLOGICAL MARKER;

DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; EPIDEMIC; EVALUATION; HEART CATHETERIZATION; HUMAN; MORBIDITY; MORTALITY; NON INVASIVE PROCEDURE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SCLERODERMA; SCREENING; SURVIVAL TIME; SYSTEMIC SCLEROSIS;

BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 82955235654     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834ba6a7     Document Type: Review

References (53)

1. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52:3792-3800. (Pubitemid 41798217)
2. Mukerjee D, St GD, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088-1093. (Pubitemid 37323574)
3. Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009; 39:682-691.
4. Avouac J, Airo P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and meta-analysis of 5 studies. J Rheumatol 2010; 37:2290-2298.
5. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34:1219-1263.
6. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940-944. (Pubitemid 46999798)
7. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54:3043-3050. (Pubitemid 44497786)
8. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:5S-12S. (Pubitemid 38759712)
9. Hachulla E, de GP, Gressin V, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60:1831-1839.
10. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well being. Rheum Dis Clin North Am 2003; 29:255-273; vi. (Pubitemid 36765120)
11. Coral-Alvarado P, Rojas-Villarraga A, Latorre MC, et al. Risk factors associated with pulmonary arterial hypertension; in Colombian patients with systematic sclerosis: review of the literature. J Rheumatol 2008; 35:244-250. (Pubitemid 351281145)
12. Hachulla E, Launay D, Mouthon L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009; 136:1211-1219.
13. Chang B, Schachna L, White B, et al. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33:269-274. (Pubitemid 43209302)
14. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40:453-459.
15. Scorza R, Caronni M, Bazzi S, et al. Postmenopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002; 966:238-246. (Pubitemid 34729180)
16. Cox SR, Walker JG, Coleman M, et al. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005; 35:28-33. (Pubitemid 40254764)
17. Robert-Thomson PJ, Mould TL, Walker JG, et al. Clinical utility of telangiectasia of hands in scleroderma and other rheumatic disorders. Asian Pac J Allergy Immunol 2002; 20:7-12. (Pubitemid 34752188)
18. Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol 2010; 37:98-104.
19. Ong YY, Nikoloutsopoulos T, Bond CP, et al. Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Asian Pac J Allergy Immunol 1998; 16:81-86. (Pubitemid 29004827)
20. Khimdas S, Harding S, Bonner A, et al. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry. Arthritis Care Res (Hoboken ) 2011; 63:142-149.
21. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48:516-522. (Pubitemid 36278021)
22. Kawut SM, Taichman DB, rcher-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123:344-350. (Pubitemid 36269414)
23. Koh ET, Lee P, Gladman DD, bu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35:989-993.
24. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106:1477-1482.
25. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40:780-788. (Pubitemid 34925627)
26. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023-1030.
27. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue diseaseassociated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179:151-157.
28. Hachulla E, Carpentier P, Gressin V, et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology (Oxford) 2009; 48:304-308.
29. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537.
30. Hachulla E, Denton CP. Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. Eur Respir Rev 2010; 19:314-320.
31. Vachiery JL, Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009; 18:162-169.
32. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248-1254. (Pubitemid 351860934)
33. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58:284-291.
34. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol 2010; 37:2064-2070.
35. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27:1485-1494. (Pubitemid 43998084)
36. Vonk M CGBDeal. The DETECT study: a two-stage, prospective, observational, cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension. Clin Exp Rheumatol 2010; 28(Suppl):55.
37. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 2004; 63:1009-1014. (Pubitemid 39120347)
38. Rich S. Primary pulmonary hypertension. Curr Treat Options Cardiovasc Med 2000; 2:135-140.
39. de GP, Gressin V, Hachulla E, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67:31-36.
40. Dorfmuller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38:893-902. (Pubitemid 46735956)
41. Montani D, Achouh L, Dorfmuller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87:220-233.
42. Rabiller A, Jais X, Hamid A, et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 2006; 27:108-113. (Pubitemid 43092673)
43. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60:569-577.
44. Le PJ, Girgis RE, Lechtzin N, et al. Systemic sclerosis related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011; 63:2456-2464.
45. Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92:926-932. (Pubitemid 43974055)
46. Hachulla E, Launay D, Yaici A, et al. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology (Oxford) 2010; 49:940-944.
47. Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis 1988; 31:205-238. (Pubitemid 19003484)
48. Hachulla E, Bervar JF, Launay D, et al. Dyspnea upon exertion in systemic scleroderma: from symptom to etiological diagnosis. Presse Med 2009; 38:911-926.
49. Launay D, Sitbon O, Le PJ, et al. Long-term outcome of systemic sclerosisassociated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010; 49:490-500.
50. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138:1383-1394.
51. Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63:783-794.
52. Christmann RB, Hayes E, Pendergrass S, et al. Interferon and alternative activation of monocyte/macrophages in systemic sclerosisassociated pulmonary arterial hypertension. Arthritis Rheum 2011; 63: 1718-1728.
53. Pendergrass SA, Hayes E, Farina G, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 2010; 5:e12106.